PROM1 and hepatocellular carcinoma: A recent study by Li et al. [25] found that a derivative of isocorydine (d-ICD) inhibited HCC cells growth, especially among the CD133+ subpopulation, and rendered that HCC cells are more sensitive to sorafenib treatment.